Bellwether Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Bellwether Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-88	Closed	-$4.28K	–	229
2025 Q2	$4.28K	Hold	88	–	–	﹤0.01%	436
2025 Q1	$3K	Hold	88	–	–	﹤0.01%	411
2024 Q4	$3.46K	Buy	+88	New	+$4.16K	﹤0.01%	410
2023 Q2	–	Sell	-88	Closed	-$3.98K	–	160
2023 Q1	$3.98K	Hold	88	–	–	﹤0.01%	316
2022 Q4	$3.58K	Hold	88	–	–	﹤0.01%	324
2022 Q3	$5K	Hold	88	–	–	﹤0.01%	318
2022 Q2	$5K	Hold	88	–	–	﹤0.01%	276
2022 Q1	$5K	Hold	88	–	–	﹤0.01%	357
2021 Q4	$6K	Hold	88	–	–	﹤0.01%	370
2021 Q3	$9K	Hold	88	–	–	﹤0.01%	312
2021 Q2	$14K	Hold	88	–	–	﹤0.01%	242
2021 Q1	$10K	Hold	88	–	–	﹤0.01%	248
2020 Q4	$13K	Buy	+88	New	+$10.4K	0.01%	214

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellwether Advisors's CRSP Position: Q3 2025 in Review

Bellwether Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 88 shares — an estimated $4.28K sold.

Bellwether Advisors first reported a position in CRSP in Q4 2020 and held it in 13 quarters. The position peaked at $14K in Q2 2021. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Bellwether Advisors reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Bellwether Advisors sold 88 CRISPR Therapeutics shares in Q3 2025, an estimated $4.28K.
Bellwether Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 13 quarters.
Bellwether Advisors's CRISPR Therapeutics position peaked at $14K in Q2 2021.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Bellwether Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.